A humanized mouse model of HPV-associated pathology driven by E7 expression Articles uri icon

authors

  • BUITRAGO-PEREZ, AGUEDA
  • HACHIMI, MARIAM
  • DUEÑAS, MARTA
  • LLOVERAS, BELEN
  • SANTOS, ALMUDENA
  • HOLGUIN, ALMUDENA
  • DUARTE, BLANCA
  • SANTIAGO, JUAN LUIS
  • AKGUL, BAKI
  • RODRIGUEZ-PERALTO, JOSE L.
  • STOREY, ALAN
  • RIVAS, CATALINA
  • LARCHER LAGUZZI, FERNANDO
  • RIO NECHAEVSKY, MARCELA ANDREA DEL
  • PARAMIO, JESUS M.
  • GARCIA-ESCUDERO, RAMON

publication date

  • July 2012

start page

  • 1

end page

  • 19

issue

  • 7(e41743)

volume

  • 7

international standard serial number (ISSN)

  • 1932-6203

abstract

  • Human papillomavirus (HPV) is the causative agent of human cervical cancer and has been associated with oropharyngeal squamous cell carcinoma development. Although prophylactic vaccines have been developed, there is a need to develop new targeted therapies for individuals affected with malignant infected lesions in these locations, which must be tested in appropriate models. Cutaneous beta HPV types appear to be involved in skin carcinogenesis. Virus oncogenicity is partly achieved by inactivation of retinoblastoma protein family members by the viral E7 gene. Here we show that the E7 protein of cutaneous beta HPV5 binds pRb and promotes its degradation. In addition, we described an in vivo model of HPV-associated disease in which artificial human skin prepared using primary keratinocytes engineered to express the E7 protein is engrafted onto nude mice. Expression of E7 in the transplants was stably maintained for up to 6 months, inducing the appearance of lesions that, in the case of HPV16 E7, histologically resembled human anogenital lesions caused by oncogenic HPVs. Moreover, it was confirmed through biomarker expression analysis via immunodetection and/or quantitative PCR from mRNA and miRNA that the 16E7-modified engrafted skin shares molecular features with human HPV-associated pretumoral and tumoral lesions. Finally, our findings indicate a decrease of the in vitro capacity of HPV5 E7 to reduce pRb levels in vivo, possibly explaining the phenotypical differences when compared with 16E7-grafts. Our model seems to be a valuable platform for basic research into HPV oncogenesis and preclinical testing of HPV-associated antitumor therapies.

keywords

  • cancer; therapeutics; clinical trials; women-health; human-papillomavirus type-16; cervical-carcinoma